Financhill
Back

Novo Nordisk AS Quote, Financials, Valuation and Earnings

Novo Nordisk AS Price Quote

$111.96
-1.28 (-1.13%)
(Updated: October 31, 2024 at 6:45 PM ET)

Novo Nordisk AS Key Stats

Sell
39
Novo Nordisk AS (NVO) is a Sell

Day range:
$107.24 - $113.76
52-week range:
$94.73 - $148.15
Dividend yield:
1.29%
P/E ratio:
41.42
P/S ratio:
13.39
P/B ratio:
30.85%

Volume:
11M
Avg. volume:
4.9M
1-year change:
17.47%
Market cap:
$498.3B
Revenue:
$33.7B
EPS:
$2.91

How Much Does Novo Nordisk AS Make?

Is Novo Nordisk AS Growing As A Company?

  • What Is Novo Nordisk AS's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.24%
  • What Is Novo Nordisk AS's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0.03%

Novo Nordisk AS Stock Price Performance

  • Did Novo Nordisk AS Stock Go Up Last Month?
    Novo Nordisk AS share price went down by -4.9% last month
  • Did NVO's Share Price Rise Over The Last Year?
    NVO share price rose by 17.47% over the past 1 year

What Is Novo Nordisk AS 52-Week High & Low?

Novo Nordisk AS Price To Free Cash Flow

Is It Risky To Buy Novo Nordisk AS?

  • How Much Debt Does Novo Nordisk AS Have?
    Total long term debt quarterly is $8.2B
  • How Much Cash Does Novo Nordisk AS Have?
    Cash and short term investments quarterly total is $9B
  • What Is Novo Nordisk AS’s Book Value Per Share?
    Book value per share is 3.63

Is Novo Nordisk AS Cash Flow Positive?

  • What Is NVO Cash Flow From Operations?
    Cash flow from operations (TTM) is $16.6B
  • What Is Novo Nordisk AS’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$5.7B
  • What Is Novo Nordisk AS’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$6.5B

Novo Nordisk AS Return On Invested Capital

  • Is Management Doing A Good Job?
    NVO return on invested capital is 68.37%
  • What Is Novo Nordisk AS Return On Assets?
    ROA measures how assets are converting to revenues and is 28.81%
  • What Is NVO Return On Equity?
    ROE is a measure of profitability and is 89.79%

Novo Nordisk AS Earnings Date & Stock Price

Novo Nordisk AS Competitors

  • Who Are Novo Nordisk AS's Competitors?
    Below is a list of companies who compete with Novo Nordisk AS or are related in some way:
    • Adaptimmune Therapeutics PLC (ADAP)
    • Amgen Inc (AMGN)
    • Evaxion Biotech AS (EVAX)
    • Genfit SA (GNFT)
    • Viking Therapeutics Inc (VKTX)

Novo Nordisk AS Dividend Yield

Novo Nordisk AS Analyst Estimates

YoY Growth Past Surprise
EPS: 2.65% -7.7%
Revenue: 23.79% -0.96%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 2
Sell Recommendations: 2
Price Target: 135.31
Upside from Last Price: 19.49%

Major Shareholders

  • How many NVO shares are owned by institutional investors?
    448.3M NVO shares are owned by institutional investors
  • How many NVO shares are owned by insiders?
    0 NVO shares are owned by insiders